MARKET

EXEL

EXEL

Exelixis Inc
NASDAQ
43.83
-0.21
-0.48%
After Hours: 43.71 -0.12 -0.27% 19:56 12/31 EST
OPEN
43.94
PREV CLOSE
44.04
HIGH
44.22
LOW
43.50
VOLUME
1.76M
TURNOVER
--
52 WEEK HIGH
49.62
52 WEEK LOW
31.90
MARKET CAP
11.75B
P/E (TTM)
18.45
1D
5D
1M
3M
1Y
5Y
1D
Noteworthy ETF Inflows: XBI, FOLD, MRNA, EXEL
NASDAQ · 12/29/2025 15:59
Weekly Report: what happened at EXEL last week (1222-1226)?
Weekly Report · 12/29/2025 10:04
Weekly Report: what happened at EXEL last week (1215-1219)?
Weekly Report · 12/22/2025 10:04
Exelixis (EXEL): Has the Recent Share Price Surge Closed the Valuation Gap?
Simply Wall St · 12/20/2025 15:24
Exelixis and Merck Advance LITESPARK-033: A New Kidney Cancer Combo With High-Stakes Market Potential
TipRanks · 12/19/2025 16:31
Weekly Report: what happened at EXEL last week (1208-1212)?
Weekly Report · 12/15/2025 10:10
Is Incyte Stock Outperforming the Nasdaq?
Barchart · 12/15/2025 07:21
Analysts Are Bullish on Top Healthcare Stocks: Owlet (OWLT), Exelixis (EXEL)
TipRanks · 12/13/2025 16:20
More
About EXEL
Exelixis, Inc. is an oncology company. The Company has produced four marketed pharmaceutical products, two of which are formulations of its flagship molecule, cabozantinib. It is also advancing and evolving its product pipeline portfolio, including its lead investigational asset, zanzalintinib. Cabozantinib is an inhibitor of multiple tyrosine kinases, including MET, AXL, VEGF receptors and RET and has been also approved as CABOMETYX tablets for advanced renal cell carcinoma, for previously treated hepatocellular carcinoma and for previously treated, radioactive iodine-refractory differentiated thyroid cancer, and as COMETRIQ capsules for progressive, metastatic medullary thyroid cancer. The Company's other two products are COTELLIC, an inhibitor of MEK approved as part of multiple combination regimens to treat specific forms of advanced melanoma and MINNEBRO an oral, non-steroidal, selective blocker of the mineralocorticoid receptor approved the treatment of hypertension in Japan.

Webull offers Exelixis Inc stock information, including NASDAQ: EXEL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, EXEL stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading EXEL stock methods without spending real money on the virtual paper trading platform.